Cellular Origins, a TTP company that enables the manufacturing of cell therapies at scale, has announced the completion of a $40 million over-subscribed Series A round.
Cell and Gene Therapy Catapult (CGT Catapult) has established a consortium to demonstrate how safety tests that detect potentially dangerous undifferentiated residual cells, which can affect product purity, could be applied to cell therapies.
TrakCel, a provider of integrated cell and gene therapy (CGT) orchestration solutions, has launched CGT Gateway to help Health Care Providers (HCPs) ease the management of cell and gene therapy products with a Single Sign-On (SSO) process.
With so much investor interest surrounding the potential of allogeneic CAR T cell therapies, the stakes are high for innovators to ensure that their inventions are robustly protected from the start.
During a recent visit to ReiThera's facilities, I saw first-hand how the company is leveraging decades of vector expertise, manufacturing capabilities, and a focus on quality to help clients bring gene therapies and vaccines from concept to clinic.
Lonza, a contract development and manufacturing organisation (CDMO), has announced the launch of TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium to expand its GMP solutions for cell and gene therapy.
SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, has announced the launch of NK.SET.
eXmoor Pharma, the integrated cell and gene therapy CDMO, has announced a new strategic partnership with Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS).
